• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Front Immunol . Genetic signatures of AKT1 variants associated with worse COVID-19 outcomes - a multicentric observational study

tetano

Editor, Senior Moderator
Front Immunol


. 2024 Oct 8:15:1422349.
doi: 10.3389/fimmu.2024.1422349. eCollection 2024. Genetic signatures of AKT1 variants associated with worse COVID-19 outcomes - a multicentric observational study

Ingrid Marins de Almeida[SUP] 1 [/SUP], Bruna Ramos Tosta[SUP] 1 [/SUP], Laiane da Cruz Pena[SUP] 1 [/SUP], Hatilla Dos Santos Silva[SUP] 1 [/SUP], Fabiane S Reis-Goes[SUP] 2 [/SUP], Nívia N Silva[SUP] 2 [/SUP], João Victor Andrade Cruz[SUP] 1 [/SUP], Mailane Dos Anjos Silva[SUP] 1 [/SUP], Jéssica Francisco de Araújo[SUP] 1 [/SUP], Juliana Lopes Rodrigues[SUP] 1 [/SUP], Gabriella Oliveira[SUP] 3 [/SUP], Ricardo Gassmann Figueiredo[SUP] 4 [/SUP], Sara Nunes Vaz[SUP] 5 [/SUP], Iris Montaño-Castellón[SUP] 5 [/SUP], Daniele Santana[SUP] 5 [/SUP], Alex Torres[SUP] 2 [/SUP], Fabyan Esberard de Lima Beltrão[SUP] 6 [/SUP], Valdirene Leão Carneiro[SUP] 7 [/SUP], Gubio Soares Campos[SUP] 8 [/SUP], Carlos Brites[SUP] 5 [/SUP], Vitor Fortuna[SUP] 2 [/SUP], Camila Alexandrina Figueiredo[SUP] 1 [/SUP], Soraya Castro Trindade[SUP] 2 4 [/SUP], Helton Estrela Ramos[SUP] 9 [/SUP], Ryan Dos Santos Costa[SUP] 1 [/SUP]



Affiliations
Abstract

Introduction: The COVID-19, triggered by the SARS-CoV-2 virus, has varied clinical manifestations, ranging from mild cases to severe forms such as fatal pneumonia and acute respiratory distress syndrome (ARDS). Disease severity is influenced by an exacerbated immune response, characterized by high pro-inflammatory cytokine levels. Inhibition of AKT can potentially suppress pathological inflammation, cytokine storm and platelet activation associated with COVID-19. In this study, we aimed to investigate the rs2494746 and rs1130214 variants in the AKT1 gene associated with severe COVID-19 outcomes.
Methods: Peripheral blood samples and sociodemographic data from 508 individuals with COVID-19, measuring plasma cytokine concentrations using ELISA and genotyped the AKT1 variants.
Results: The rs2494746-C allele was associated with severity, ICU admission, and death from COVID-19. The C allele at rs1130214 was linked to increased TNF and D-dimer levels. Moreover, both variants exhibited an increased cumulative risk of disease severity, ICU admission, and mortality caused by COVID-19. In the predictive analysis, the rs2494746 obtained an accuracy of 71%, suggesting a high probability of the test determining the severity of the disease.
Discussion: Our findings contribute to understanding the influence of the AKT1 gene variants on the immunological damage in individuals infected with SARS-CoV-2.

Keywords: AKT1; COVID-19; immunogenetics; polymorphism; severity.

 
Back
Top Bottom